nach oben

Erschienen in:

05.08.2019 | Review

Pictorial review on abdominal applications of ferumoxytol in MR imaging

verfasst von: Hamed Kordbacheh, Vinit Baliyan, Anushri Parakh, Gregory R. Wojtkiewicz, Sandeep Hedgire, Mukesh G. Harisinghani

Erschienen in: Abdominal Radiology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Though gadolinium-based contrast agents are the most widely used contrast media in MR for clinical use, problems with nephrogenic systemic fibrosis and tissue deposition render their safety debatable, at least in a selected patient population. Ferumoxytol has the potential to be used as an alternate contrast medium for various clinical applications across multiple organs. It has prolonged intravascular signal and delayed intracellular macrophage uptake which are unique properties compared to gadolinium-based agents. This pictorial review aims to review the current and potential clinical applications of ferumoxytol as a contrast agent in abdominal MR imaging.

Research C for DE and. Drug Safety and Availability - FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings [Internet]. [cited 2018 Jul 28]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm

Tedeschi E, Caranci F, Giordano F, Angelini V, Cocozza S, Brunetti A. Gadolinium retention in the body: what we know and what we can do. Radiol Med (Torino). 2017 Aug;122(8):589–600.CrossRef

Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2010 Jan;30(1):15–35.CrossRef

Auerbach M, Chertow GM, Rosner M. Ferumoxytol for the treatment of iron deficiency anemia. Expert Rev Hematol. 2018 Sep 6;0(ja):null.

Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging JMRI. 2015 Apr;41(4):884–98.CrossRefPubMed

Toth GB, Varallyay CG, Horvath A, Bashir MR, Choyke PL, Daldrup-Link HE, et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int. 2017;92(1):47–66.CrossRefPubMedPubMedCentral

Auerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Am J Hematol. 2013 Nov;88(11):944–7.CrossRefPubMed

Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010 May;85(5):315–9.PubMed

Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol CJASN. 2014 Apr;9(4):705–12.CrossRefPubMed

10.

Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, et al. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol. 2014 Jan;89(1):7–12.CrossRefPubMed

11.

Schiller B, Bhat P, Sharma A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther. 2014 Jan 1;36(1):70–83.CrossRefPubMed

12.

Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol. 2014 Jun;89(6):646–50.CrossRefPubMedPubMedCentral

13.

Research C for DE and. Drug Safety and Availability - FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol) [Internet]. [cited 2018 Jul 28]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm440138.htm

14.

Neuwelt EA, Várallyay CG, Manninger S, Solymosi D, Haluska M, Hunt MA, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery. 2007 Apr;60(4):601–11; discussion 611-612.

15.

Hope MD, Hope TA, Zhu C, Faraji F, Haraldsson H, Ordovas KG, et al. Vascular Imaging With Ferumoxytol as a Contrast Agent. AJR Am J Roentgenol. 2015 Sep;205(3):W366-373.CrossRefPubMedPubMedCentral

16.

Storey P, Arbini AA. Bone marrow uptake of ferumoxytol: a preliminary study in healthy human subjects. J Magn Reson Imaging JMRI. 2014 Jun;39(6):1401–10.CrossRefPubMed

17.

Storey P, Lim RP, Chandarana H, Rosenkrantz AB, Kim D, Stoffel DR, et al. MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Invest Radiol. 2012 Dec;47(12):717–24.CrossRefPubMed

18.

Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann H-J. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005 Nov;40(11):715–24.CrossRefPubMed

19.

Knobloch G, Colgan T, Wiens CN, Wang X, Schubert T, Hernando D, et al. Relaxivity of Ferumoxytol at 1.5 T and 3.0 T. Invest Radiol. 2018 May;53(5):257–63.

20.

Yang L-J. Big Mac Attack: Does It Play a Direct Role for Monocytes/Macrophages in Type 1 Diabetes? Diabetes. 2008 Nov;57(11):2922–3.CrossRefPubMedPubMedCentral

21.

Fu W, Wojtkiewicz G, Weissleder R, Benoist C, Mathis D. Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat Immunol. 2012 Feb 26;13(4):361–8.CrossRefPubMedPubMedCentral

22.

Gaglia JL, Harisinghani M, Aganj I, Wojtkiewicz GR, Hedgire S, Benoist C, et al. Noninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients. Proc Natl Acad Sci. 2015 Feb 17;112(7):2139–44.CrossRefPubMed

23.

Turvey SE, Swart E, Denis MC, Mahmood U, Benoist C, Weissleder R, et al. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J Clin Invest. 2005 Sep;115(9):2454–61.CrossRefPubMedPubMedCentral

24.

Denis MC, Mahmood U, Benoist C, Mathis D, Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12634–9.CrossRefPubMedPubMedCentral

25.

Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanoparticles. Nat Mater. 2014 Feb;13(2):125–38.CrossRefPubMed

26.

Kaitha S, Bashir M, Ali T. Iron deficiency anemia in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2015 Aug 15;6(3):62–72.CrossRefPubMedPubMedCentral

27.

Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007 Dec;13(12):1545–53.CrossRefPubMed

28.

Ford DC, Dahl NV, Strauss WE, Barish CF, Hetzel DJ, Bernard K, et al. Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders. Clin Exp Gastroenterol. 2016 Jul 11;9:151–62.

29.

30.

Moy MP, Sauk J, Gee MS. The Role of MR Enterography in Assessing Crohn’s Disease Activity and Treatment Response [Internet]. Gastroenterology Research and Practice. 2016 [cited 2018 Jun 30]. Available from: https://www.hindawi.com/journals/grp/2016/8168695/

31.

Wu Y, Briley-Saebo K, Xie J, Zhang R, Wang Z, He C, et al. Inflammatory Bowel Disease: MR- and SPECT/CT-based Macrophage Imaging for Monitoring and Evaluating Disease Activity in Experimental Mouse Model—Pilot Study. Radiology. 2014 Jan 15;271(2):400–7.CrossRefPubMed

32.

Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007 Dec 1;26(3–4):373–400.CrossRefPubMed

33.

Jakubowska K, Kisielewski W, Kańczuga-Koda L, Koda M, Famulski W. Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer. Oncol Lett. 2017 Sep;14(3):3869–77.CrossRefPubMedPubMedCentral

34.

Steele CW, Kaur Gill NA, Jamieson NB, Carter CR. Targeting inflammation in pancreatic cancer: Clinical translation. World J Gastrointest Oncol. 2016 Apr 15;8(4):380–8.CrossRefPubMedPubMedCentral

35.

Hedgire SS, Mino-Kenudson M, Elmi A, Thayer S, Fernandez-del Castillo C, Harisinghani MG. Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation. Int J Nanomedicine. 2014;9:1891–6.CrossRefPubMedPubMedCentral

36.

Ganeshalingam S, Koh D-M. Nodal staging. Cancer Imaging. 2009 Dec 24;9(1):104–11.CrossRefPubMedPubMedCentral

37.

Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology. 1990 May;175(2):489–93.CrossRefPubMed

38.

Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology. 1990 May;175(2):494–8.CrossRefPubMed

39.

Hudgins PA, Anzai Y, Morris MR, Lucas MA. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol. 2002 Apr;23(4):649–56.PubMed

40.

Bourrinet P, Bengele HH, Bonnemain B, Dencausse A, Idee J-M, Jacobs PM, et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol. 2006 Mar;41(3):313–24.CrossRefPubMed

41.

Harisinghani M, Ross RW, Guimaraes AR, Weissleder R. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia N Y N. 2007 Dec;9(12):1160–5.CrossRef

42.

Hedgire SS, Oei TN, McDermott S, Cao K, Patel M Z, Harisinghani MG. Multiparametric magnetic resonance imaging of prostate cancer. Indian J Radiol Imaging. 2012 Jul;22(3):160–9.CrossRefPubMedPubMedCentral

43.

Tabatabaei S, Harisinghani M, McDougal WS. Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol. 2005 Sep;174(3):923–7; discussion 927.

44.

Zhang F, Zhu L, Huang X, Niu G, Chen X. Differentiation of reactive and tumor metastatic lymph nodes with diffusion-weighted and SPIO-enhanced MRI. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2013 Feb;15(1):40–7.CrossRef

45.

Weissleder R, Elizondo G, Josephson L, Compton CC, Fretz CJ, Stark DD, et al. Experimental lymph node metastases: enhanced detection with MR lymphography. Radiology. 1989 Jun;171(3):835–9.CrossRefPubMed

46.

Kallianos K, Henry TS, Yeghiazarians Y, Zimmet J, Shunk KA, Tseng EE, et al. Ferumoxytol MRA for transcatheter aortic valve replacement planning with renal insufficiency. Int J Cardiol. 2017 Mar 15;231:255–7.CrossRef

47.

Nguyen K-L, Moriarty JM, Plotnik AN, Aksoy O, Yoshida T, Shemin RJ, et al. Ferumoxytol-enhanced MR Angiography for Vascular Access Mapping before Transcatheter Aortic Valve Replacement in Patients with Renal Impairment: A Step Toward Patient-specific Care. Radiology. 2018;286(1):326–37.CrossRefPubMed

48.

Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C13-18.CrossRefPubMed

49.

MA3RS Study Investigators. Aortic Wall Inflammation Predicts Abdominal Aortic Aneurysm Expansion, Rupture, and Need for Surgical Repair. Circulation. 2017 Aug 29;136(9):787–97.

50.

Hedgire S, Krebill C, Wojtkiewicz GR, Oliveira I, Ghoshhajra BB, Hoffmann U, et al. Ultrasmall superparamagnetic iron oxide nanoparticle uptake as noninvasive marker of aortic wall inflammation on MRI: proof of concept study. Br J Radiol. 2018 Dec;91(1092):20180461.CrossRefPubMed

51.

MacDONALD RA, Mallory GK. Hemochromatosis and Hemosiderosis: Study of 211 Autopsied Cases. AMA Arch Intern Med. 1960 May 1;105(5):686–700.CrossRefPubMed

52.

Drakonaki E, Papakonstantinou O, Maris T, Vasiliadou A, Papadakis A, Gourtsoyiannis N. Adrenal glands in beta-thalassemia major: magnetic resonance (MR) imaging features and correlation with iron stores. Eur Radiol. 2005 Dec;15(12):2462–8.CrossRefPubMed

53.

Gunn AJ, Seethamraju RT, Hedgire S, Elmi A, Daniels GH, Harisinghani MG. Imaging behavior of the normal adrenal on ferumoxytol-enhanced MRI: preliminary findings. AJR Am J Roentgenol. 2013 Jul;201(1):117–21.CrossRefPubMed

54.

Gultepe E, Reynoso FJ, Jhaveri A, Kulkarni P, Nagesha D, Ferris C, et al. Monitoring of magnetic targeting to tumor vasculature through MRI and biodistribution. Nanomed. 2010 Oct;5(8):1173–82.CrossRef

55.

Hayano K, Miura F, Wada K, Suzuki K, Takeshita K, Amano H, et al. Diffusion-weighted MR imaging of pancreatic cancer and inflammation: Prognostic significance of pancreatic inflammation in pancreatic cancer patients. Pancreatology. 2016 Jan 1;16(1):121–6.CrossRefPubMed

56.

Finn JP, Nguyen K-L, Han F, Zhou Z, Salusky I, Ayad I, et al. Cardiovascular MRI with ferumoxytol. Clin Radiol. 2016 Aug;71(8):796–806.CrossRefPubMed

57.

Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Safety of Ferumoxytol in Patients With Anemia and CKD. Am J Kidney Dis. 2008 Nov 1;52(5):907–15.CrossRefPubMed

58.

Adkinson NF, Strauss WE, Macdougall IC, Bernard KE, Auerbach M, Kaper RF, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. Am J Hematol. 93(5):683–90.

Titel: Pictorial review on abdominal applications of ferumoxytol in MR imaging
verfasst von: Hamed Kordbacheh
Vinit Baliyan
Anushri Parakh
Gregory R. Wojtkiewicz
Sandeep Hedgire
Mukesh G. Harisinghani
Publikationsdatum: 05.08.2019
Verlag: Springer US
Erschienen in: Abdominal Radiology / Ausgabe 10/2019
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-019-02163-4

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Pictorial review on abdominal applications of ferumoxytol in MR imaging

Abstract

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Comparison of two small bowel distending agents for enterography in pediatric small bowel imaging

Comparison of MR imaging features of uterine neuroendocrine carcinoma and uterine malignant lymphoma

Validation of SE-EPI-based T2 mapping for characterization of prostate cancer: a new method compared with the traditional CPMG method

Mickey mouse sign

Jejunoileal fold pattern reversal in celiac disease

Characterization of adrenal lesions on chemical shift MRI: comparison of 1.5 T and 3 T MRI

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie